|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| (Gain) loss on sales of securities | |||||
| Realized losses on available-for-sale securities | |||||
| Realized (gain) loss on available-for-sale securities | |||||
| Loss (gain) on disposal of fixed assets | |||||
| Stock based compensation expense | |||||
| Credit loss expense - loans | |||||
| Credit loss (benefit) - debt securities held-to-maturity | |||||
| Depreciation and amortization | |||||
| Net (accretion) amortization on securities premiums and discounts | |||||
| Accretion of discounts for loans acquired and net deferred loan fees | |||||
| Increase in cash surrender value of life insurance policies | |||||
| Amortization of core deposit intangible | |||||
| Decrease (increase) in interest receivable and other assets | |||||
| (Decrease) increase in other liabilities | |||||
| Deferred income tax (benefit) provision | |||||
| Decrease in equity securities | |||||
| Net amortization of partnership investment | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Maturities and calls of debt securities available-for-sale | |||||
| Proceeds from sales of debt securities available-for-sale | |||||
| Purchases of debt securities available-for-sale | |||||
| Principal paydowns on debt securities available-for-sale | |||||
| Maturities and calls of debt securities held-to-maturity | |||||
| Principal paydowns on debt securities held-to-maturity | |||||
| Purchases of FHLB stock | |||||
| Loan (originations) and payments, net | |||||
| Purchases of premises and equipment | |||||
| Proceeds from sales of fixed assets | |||||
| Proceeds from sales of premises and equipment | |||||
| Proceeds from sales of foreclosed assets | |||||
| Purchase of separate account life insurance | |||||
| Purchase of split dollar life insurance | |||||
| Liquidation of bank-owned life insurance | |||||
| Proceeds from bank-owned life insurance death benefit | |||||
| Amortization of debt issuance costs | |||||
| Net increase in partnership investment | |||||
| Net cash (used in) provided by investing activities | |||||
| Cash flows from financing activities: | |||||
| (Decrease) increase in deposits | |||||
| Increase (decrease) in fed funds purchased | |||||
| Increase (decrease) in short-term borrowed funds | |||||
| Proceeds from long-term Federal Home Loan Bank advances and other debt | |||||
| Increase (decrease) in repurchase agreements | |||||
| Cash dividends paid | |||||
| Repurchases of common stock | |||||
| Stock options exercised | |||||
| Net cash provided by (used in) financing activities | |||||
| Increase in cash and due from banks | |||||
| Cash and cash equivalents, beginning of year | |||||
| Cash and cash equivalents, end of year | |||||
| Supplemental disclosure of cash flow information: | |||||
| Interest | |||||
| Income taxes | |||||
| Supplemental disclosure of noncash investing and financing activities: | |||||
| Real estate acquired through foreclosure | |||||
| Operating right-of-use asset from branch facilities sale leaseback transaction | |||||
| Operating lease liability from branch facilities sale leaseback transaction | |||||
| Right-of-use assets obtained in exchange for new lease liabilities (excluding sale/leaseback) | |||||
Loading...